Zobrazeno 1 - 10
of 24
pro vyhledávání: '"F W Asselbergs"'
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172082 (2017)
BACKGROUND:In the past decade many Genome-wide Association Studies (GWAS) were performed that discovered new associations between single-nucleotide polymorphisms (SNPs) and various phenotypes. Imputation methods are widely used in GWAS. They facilita
Externí odkaz:
https://doaj.org/article/eeabb12f33854cf0b1e2b98cdd71e7a8
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/37d3fce4ed204e26bc7dd57398145829
Autor:
M. T. H. M. Henkens, A. G. Raafs, J. A. J. Verdonschot, M. Linschoten, M. van Smeden, P. Wang, B. H. M. van der Hooft, R. Tieleman, M. L. F. Janssen, R. M. A. ter Bekke, M. R. Hazebroek, I. C. C. van der Horst, F. W. Asselbergs, F. J. H. Magdelijns, S. R. B. Heymans, on behalf of the CAPACITY-COVID collaborative consortium
Publikováno v:
BMC Geriatrics, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Age and comorbidities increase COVID-19 related in-hospital mortality risk, but the extent by which comorbidities mediate the impact of age remains unknown. Methods In this multicenter retrospective cohort study with data from 45
Externí odkaz:
https://doaj.org/article/63cd907116554fd7aa752394ba3ba886
Autor:
Lulu S. Fundikira, P. Chillo, R. Mutagaywa, A. Kamuhabwa, G. Kwesigabo, F. W. Asselbergs, L. W. van Laake
Publikováno v:
Global Heart, Vol 17, Iss 1 (2022)
Highlights Prevalence of DCM varies widely in SSA. Cardiovascular risk factors are important in patients with DCM. The role of genetics in idiopathic DCM is not studied in major part of SSA.
Externí odkaz:
https://doaj.org/article/c4335cb9fbae4730b0299747451c6694
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/68f74543d79d4115ab226c6139b54111
Autor:
M Bourfiss, N H J Prakken, C A James, R N Planken, S M Boekholdt, D Ahmetagic, M P van den Berg, C Tichnell, J F Van der Heijden, P Loh, B Murray, H Tandri, I Kamel, H Calkins, F W Asselbergs, S L Zimmerman, B K Velthuis, A S J M Te Riele
Publikováno v:
European Heart Journal-Cardiovascular Imaging, 24(1):jeac030, 98-107. Oxford University Press
European heart journal cardiovascular Imaging, 24(1), 98-107. Oxford University Press
European heart journal cardiovascular Imaging, 24(1), 98-107. Oxford University Press
Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by ventricular dysfunction and ventricular arrhythmias (VA). Adequate arrhythmic risk assessment is important to prevent sudden cardiac death. We aimed to study the incremen
Publikováno v:
Netherlands Heart Journal. 30:190-197
Vaccines against coronavirus 2019 disease (COVID-19) have shown to be greatly effective in preventing viral spread, serious illness and death from this infectious disease and are therefore critical for the management of the COVID-19 pandemic. However
Autor:
M Van Der Heide, T E Verstraelen, F H M Van Lint, L P Bosman, R De Brouwer, V M Proost, G S Abeln, B A Schoonderwoerd, A C Houweling, J R Gimeno-Blanes, F W Asselbergs, R A De Boer, M P Van Den Berg, J P Van Tintelen, A A M Wilde
Publikováno v:
European Heart Journal. 43
Background/Introduction Recently, a variant-specific prediction model for PLN p.Arg14del variant carriers was developed to predict individual malignant ventricular arrhythmia (VA) risk to inform decision-making for primary prevention implantable card
Autor:
R De Brouwer, W P Te Rijdt, E T Hoorntje, J C Karper, B D Westenbrink, A S J M Te Riele, J F Van Der Heijden, A Amin, J P Van Tintelen, F W Asselbergs, A A M Wilde, R A De Boer, M P Van Den Berg
Publikováno v:
European Heart Journal. 43
Background A pathogenic variant in the gene encoding phospholamban (PLN; p.Arg14del) may cause cardiomyopathy, the pathophysiologic hallmark of which is cardiac fibrosis that may cause malignant ventricular arrhythmias and severe heart failure. There
Autor:
H. M. Nathoe, Ynte M. Ruigrok, M. L. Bots, Miriam P van der Meulen, M.I. Geerlings, Frank L.J. Visseren, F.L.J. Visseren, J Westerink, Arend Mosterd, Steven H J Hageman, N P van der Kaaij, Michiel L. Bots, Folkert W. Asselbergs, Tim Leiner, M H Emmelot, Jan Westerink, P A de Jong, Marianne C. Verhaar, Jannick A N Dorresteijn, A T Lely, F W Asselbergs, G.J. de Borst, L.J. Kappelle
Publikováno v:
European Journal of Preventive Cardiology. 29:635-644
Aims To determine the (cost)-effectiveness of blood pressure lowering, lipid-lowering, and antithrombotic therapy guided by predicted lifetime benefit compared to risk factor levels in patients with symptomatic atherosclerotic disease. Methods and re